Table 5. Vaccine type availability and factors that influence choice of vaccine type by the GP in 2019/2020, by risk group, Italy.
| ITALY | 10-17y with chronic conditions | 18-64y with chronic conditions | ≥65y | 65-74y | ≥75y |
|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | n (%) | |
| Vaccine types available | (N = 139) | (N = 116) | (N = 116) | ||
| 1 | 110 (79.1) | 91 (78.4) | 35 (31.0) | - | - |
| >1 | 29 (20.9) | 25 (21.6) | 81 (69.8) | - | - |
| >1 excluding aTIV | - | - | 4 (3.4) | - | - |
| >1 including aTIV | - | - | 77 (66.4) | - | - |
| Frequency with which GP chooses aTIV a | (N = 77) | (N = 76) | |||
| Always | - | - | - | 8 (10.4) | 21 (27.6) |
| Usually | - | - | - | 31 (40.3) | 44 (57.9) |
| Sometimes | - | - | - | 23 (29.9) | 5 (6.6) |
| Not usually | - | - | - | 13 (16.9) | 6 (7.9) |
| Never | - | - | - | 2 (2.6) | 0 (0) |
| The following factors influence choice of vaccine type by the GPb | QIVe vs QIVc (N = 4) | aTIV vs. QIVe and/or QIVc (N = 77) | aTIV vs. QIVe and/or QIVc (N = 76) | ||
| Patient preference (N = 28; 24; 4) c | 3 (10.7) | 4 (16.7) | 0 (0) | 14 (18.2) | 15 (19.7) |
| Directed by vaccine availability (N = 28; 23; 4) c | 18 (64.3) | 16 (69.6) | 4 (100) | 55 (71.4) | 56 (73.7) |
| Patient characteristics (N = 26; 24; 4) c | 9 (34.6) | 12 (50.0) | 4 (100) | 60 (77.9) | 52 (68.4) |
| The following patient characteristics influence choice of vaccine type by the GPd | (N = 8) | (N = 11) | (N = 4) | (N = 60) | (N = 52) |
| Younger age | 4 (50.0) | 3 (27.3) | 1 (25.0) | 13 (21.7) | 12 (23.1) |
| Older age | 7 (87.5) | 8 (72.7) | 1 (25.0) | 50 (83.3) | 42 (80.8) |
| Presence of multiple comorbidities | 4 (50.0) | 8 (72.7) | 3 (75.0) | 47 (78.3) | 40 (76.9) |
| Presence of specific comorbidities | 1 (12.5) | 0 (0.0) | 0 (0.0) | 15 (25.0) | 11 (21.2) |
| Higher severity of comorbidities | 1 (12.5) | 4 (36.4) | 2 (50.0) | 18 (30.0) | 16 (30.8) |
| Frailty | 3 (37.5) | 4 (36.4) | 1 (25.0) | 29 (48.3) | 22 (42.3) |
| Profession | - | 3 (27.3) | - | - | |
| Other | 1 (12.5) | 1 (9.1) | 0 (0.0) | 7 (11.7) | 7 (13.5) |
aTIV: adjuvanted trivalent influenza vaccine; n: number of GPs that chose a particular answer; N: number of GPs that answered the question; QIVe: egg-based quadrivalent influenza vaccine; QIVc: cell-based quadrivalent influenza vaccine.
a This question was only posed to GPs that answered “>1 including aTIV” to the first question.
b This question was only posed to GPs that answered “>1 type” to the first question.
c Number of GPs that answered the question for the risk groups 10-17y with chronic conditions, 18-64y with chronic conditions, and ≥65y, respectively.
d This question was only posed to GPs that answered “patient characteristics” to the previous question.